Back to MPT Database

EFdA-P + Progestin Intravaginal Film

A next generation MPT film platform for once a month intravaginal administration of 4′-Ethynyl-2-fluoro-2′-deoxyadenosine (EFdA) or the EFdA prodrug (EFdA-P) and a progestin (levonorgestrel (LNG) or etonogestrel (ENG)) to achieve the dual goal of preventing HIV infection and pregnancy.

Development Stage:

Preclinical – Early (Pre1)

Hormonal/Non-Hormonal:

Hormonal

Delivery Route & Method:

Topical - Film - Vaginal

Mechanism of Action:

Nucleoside reverse transcriptase translocation inhibitor and progestin hormonal contraceptive

Developer:

  • Magee-Women's Research Inst. & Foundation
  • University of Pittsburgh

Funding:

  • Nat. Institute Allergy & Infect. Diseases (NIAID)

Funding Mechanism:

Long Acting Film Technology for Contraception and HIV Prevention (LATCH) R61/R33 (R61AI142687 / R33AI142687) NIAID NIH

Active Ingredient(s):

  • 4'-Ethynyl-2-fluoro-2'-deoxyadenosine (EFdA)
  • 4'-Ethynyl-2-fluoro-2'-deoxyadenosine prodrug (EFdA-P)
  • Progestin

Product Indication(s):

  • HIV
  • Pregnancy

Useful Links:

Back to MPT Database